Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.12)
# 2,982
Out of 5,058 analysts
118
Total ratings
37.74%
Success rate
-3.94%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $16 → $25 | $11.59 | +115.70% | 2 | Nov 7, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $24 | $9.54 | +151.57% | 7 | Nov 6, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $24 → $28 | $29.01 | -3.48% | 4 | Nov 5, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $160 → $164 | $140.02 | +17.13% | 17 | Oct 29, 2025 | |
| ATAI Atai Beckley | Maintains: Buy | $11 → $14 | $4.01 | +249.13% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $3.72 | +356.99% | 4 | Sep 30, 2025 | |
| CLNN Clene | Maintains: Buy | $83 → $48 | $8.97 | +435.12% | 6 | Aug 18, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $5.51 | +172.23% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $9.00 | +200.00% | 6 | Jul 29, 2025 | |
| CYBN Cybin | Maintains: Buy | $73 → $70 | $6.02 | +1,062.79% | 8 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $265 → $220 | $169.78 | +29.58% | 21 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $4.30 | +179.07% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $1.89 | +4,132.80% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $14.51 | +92.97% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $23.45 | +40.72% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $9.89 | +1,416.68% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $24.80 | - | 2 | Jan 31, 2017 |
Mind Medicine (MindMed)
Nov 7, 2025
Maintains: Buy
Price Target: $16 → $25
Current: $11.59
Upside: +115.70%
Zevra Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $9.54
Upside: +151.57%
Stoke Therapeutics
Nov 5, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $29.01
Upside: -3.48%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $160 → $164
Current: $140.02
Upside: +17.13%
Atai Beckley
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $4.01
Upside: +249.13%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $3.72
Upside: +356.99%
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $8.97
Upside: +435.12%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $5.51
Upside: +172.23%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $9.00
Upside: +200.00%
Cybin
Jul 8, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $6.02
Upside: +1,062.79%
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $169.78
Upside: +29.58%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $4.30
Upside: +179.07%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.89
Upside: +4,132.80%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $14.51
Upside: +92.97%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $23.45
Upside: +40.72%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $9.89
Upside: +1,416.68%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $24.80
Upside: -